hdr isap

News January 2014

A high chocolate consumption has been linked with increased body weight but also with reduced risks for the development of cardiometabolic disorders.
This study contributes important new insights into the chocolate consumption in a hospital ward environment and the half lives of two brands of chocolates. Continue reading this study and remember the results any time you contribute to the short survival time of chocolates on hospital wards or labs.

News December 2013

Tissue concentrations again (Eng`s principle of medical procedures: „The easier it is to do, the harder it is to change.“)
Stein et al recently published a paper in the Journal of Antimicrobial Chemotherapy reporting the tissue penetration of trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection to support their use in the treatment of diabetic foot infections (JAC 2013; 68: 2852–2858). This study used tissue biopsy homogenates to determine the concentrations at the site of infection, a method that measures a mixture of total (bound+free) concentrations in intra-, extracellular and blood compartments where antibiotics and bacteria are not distributed evenly. It is difficult to discourage methods that are easy and cheap though they bring potenially misleading results.
ISAP and the ESCMID PK/PD study group submitted a response to JAC with the intention to raise awareness regarding methodological pitfalls of tissue concentration measurements.

News June 2013

The ISAP organizing committee invites young investigators to submit their abstracts (in ICAAC format) for oral presentation during the ISAP meeting. To ensure the work of different research groups are well represented, please limit one abstract submission per senior (corresponding) investigator.  The abstracts will be evaluated by a panel of independent senior scientists, based on relevance to PK/PD and scientific merits.  Please submit your abstract by email to Dr. Brian Tsuji ( This email address is being protected from spambots. You need JavaScript enabled to view it.) by July 15, 2013. Abstracts selected for presentation will be notified by August 23, 2013.

The annual meeting and post-ICAAC symposium will take place on September 13th, 2013, 2:00-6:00 PM in Denver, Collorado, USA

News November 2013

The European Medicines Agency (EMA) recently released an Addendum to the guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections. One of the most important aspects of the addendum is that it outlines a new approach facilitating the development of antibacterial agents targeted against multidrug-resistant pathogens where patients have very limited or no remaining treatment options. Accepting limited evidence of clinical safety and efficacy is strongly based on extensive preclinical and clinical PK/PD analyses. PK/PD studies may play a pivotal role in alternative study designs in indications where placebo controls are required as well as in limited pre-licensure clinical development programmes targeting multidrug-resistant pathogens.The field of PK/PD will be an essential pilar in the development of novel antibacterial drugs to treat infections due to multidrugresistant organisms that are currently uncommon or rare and for which there are few remaining therapeutic options.

News May 2013

The 1st International Conference on Polymyxins, an opinion-leader conference to present and learn of the latest findings on the polymyxin antibiotics, took place in on 2 - 4 May, 2013 at the Monash University Centre in Prato, Italy. The organizers and most members of the organizing committee are active members of ISAP: Roger Nation, Australia (Chair), Jian Li, Australia (Deputy Chair), Otto Cars, Sweden, William Couet, France, Mike Dudley, USA, Bob Hancock, Canada, Johan Mouton, Netherlands, David Paterson, Australia, Vincent Tam, USA, Ursula Theuretzbacher, Austria, Brian Tsuji, USA, John Turnidge, Australia.

Despite worldwide fast growth of basic and clinically applied knowledge several key issues such as the optimal dosing regimen (loading dose, timing of first maintenance dose and maintenance doses), potential clinic advantage of combination vs monotherapy, management strategies of nephrotoxicity, huge variability of drug exposure, role for therapeutic drug monitoring, wide quality specifications of content, confusing labelling in different countries, in vitro testing challenges, remain. Shortly, the presentations of the Polymyxin Conference will be posted on the ISAP website. Within each symposium key issues have been identified that will be summarised in the Prato Polymyxin Consensus, in which recommendations will be published to guide the clinical use of polymyxins and identify high-priority areas for further research.

Supporters of the Polymyxin Conference: ISAP, The EU funded project AIDA (Preserving old antibiotics for the future), PK/PD Study Group of ESCMID, ESCMID